AGP Picks
View all

GLX Analytix adds two neuroscientists to scientific board

3 hours ago
GLX Analytix adds two neuroscientists to scientific board
By AI, Created 16:00 UTC, Nov 17, 2026, AGP -

GLX Analytix named Dr. Diego A. Pizzagalli and Dr. Samuel Ridout to its Scientific Board as the company pushes AI-driven diagnostic and monitoring tools for neuropsychiatry and neurodegenerative disease. The appointments are meant to support development of the GLX Signature Platform and its vascular biomarker work for major depression and related conditions.

Why it matters: - GLX Analytix is betting that expert guidance from two high-profile neuroscientists will help speed clinical translation of its AI-powered biomarker platform. - The company is targeting major depression and other brain disorders where better diagnostic and monitoring tools could improve treatment selection and follow-up. - The appointments add scientific credibility as GLX Analytix expands partnerships across the U.S. for personalized care tools.

What happened: - GLX Analytix announced the appointment of Dr. Diego A. Pizzagalli and Dr. Samuel Ridout to its Scientific Board of Directors. - The announcement came Nov. 17, 2026, from Silicon Valley, California. - Brian Della Valle, founder and CEO of GLX Analytix, said the two appointments mark a significant milestone for the company. - Dr. Pizzagalli and Dr. Ridout will help guide work tied to the company’s vascular glycobiology biomarkers and clinical decision support tools.

The details: - Dr. Pizzagalli is the Founding Director of the Noel Drury, M.D. Institute for Translational Depression Discoveries at the University of California, Irvine. - Dr. Pizzagalli holds the Noel Drury M.D. Endowed Chair and is a Distinguished Professor across psychiatry and human behavior, neurobiology and behavior, and biomedical engineering at UC Irvine. - Before UC Irvine, Dr. Pizzagalli spent more than 20 years on the Harvard University faculty. - At Harvard, Dr. Pizzagalli served as Professor of Psychiatry at Harvard Medical School, Director of the Center for Depression, Anxiety, and Stress Research, and Director of the McLean Imaging Center at McLean Hospital. - Dr. Pizzagalli is also a Visiting Professor and Fellow at the University of Oxford. - Dr. Pizzagalli has authored more than 450 peer-reviewed publications. - Dr. Pizzagalli is Editor-in-Chief of Cognitive, Affective and Behavioral Neuroscience. - Dr. Pizzagalli’s research uses behavioral, neuroimaging, electrophysiological and pharmacological methods to study depression-related features including anhedonia, stress sensitivity and executive function deficits. - Dr. Pizzagalli has received two MERIT Awards from the National Institute of Mental Health, the Anna-Monika Prize for Research in the Neurobiology and Treatment of Depressive Disorders, and the CINP AsCNP Brain Health Clinical Research Award. - Dr. Pizzagalli said the GLX Signature Platform could transform therapeutic selection and monitoring for major depression and other brain conditions. - Dr. Ridout earned both his MD and PhD at The Pennsylvania State University. - Dr. Ridout’s doctoral research focused on exercise physiology and cardiac mechanisms of muscle blood flow limitation in aging women. - After medical training, Dr. Ridout completed his residency at Brown University and an NIH research fellowship. - Dr. Ridout’s research spans basic physiology, adverse childhood experiences, treatment-resistant depression and digital psychiatry. - Dr. Ridout serves on the American Psychiatric Association’s Digital Health and Information Technology Council. - Dr. Ridout is a primary investigator on multiple ongoing clinical studies in mental health and translational research. - Dr. Ridout said GLX Analytix is working to make precision psychiatry measurable and accessible through vascular glycobiology and AI. - GLX Analytix says its platform combines proprietary glycobiology insights and machine learning to support care for major depressive disorder, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease and ALS. - The company says its GLX Signature Platform uses novel vascular biology and AI technology to transform care for neurodegenerative and neuropsychiatric diseases. - GLX Analytix says it is backed by venture and strategy investors and has been recognized by industry leaders including Roche.

Between the lines: - The board additions suggest GLX Analytix is trying to bridge academic neuroscience with commercial product development. - Dr. Pizzagalli brings deep depression research expertise, while Dr. Ridout adds clinical psychiatry and digital health experience. - The mix points to a strategy centered on turning biomarker research into tools that clinicians can use in routine practice.

What's next: - GLX Analytix is expected to continue building clinical partnerships as it develops the GLX Signature Platform. - The company is positioning the board appointments to support broader validation and adoption of its diagnostic and monitoring approach. - GLX Analytix said it aims to advance accessible, cost-effective and personalized healthcare through its platform.

The bottom line: - GLX Analytix is adding heavyweight scientific advisers as it tries to turn AI-driven vascular biomarkers into practical tools for psychiatry and neurology. - More information is available through the company’s LinkedIn page.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Sci-Tech News Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Sci-Tech News Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.